

# G B John Mancini

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3553817/g-b-john-mancini-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64  
papers

3,674  
citations

28  
h-index

60  
g-index

76  
ext. papers

4,585  
ext. citations

4.4  
avg, IF

5.24  
L-index

#	Paper	IF	Citations
64	Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. <i>Circulation: Cardiovascular Interventions</i> , <b>2014</b> , 7, 645-55	6	420
63	Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 2554-60	15.1	311
62	Contemporary Review on Spontaneous Coronary Artery Dissection. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 297-312	15.1	301
61	Spontaneous Coronary Artery Dissection: Clinical Outcomes and Risk of Recurrence. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1148-1158	15.1	264
60	Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. <i>Circulation</i> , <b>1995</b> , 92, 2419-25	16.7	186
59	Atherosclerotic plaque characteristics by CT angiography identify coronary lesions that cause ischemia: a direct comparison to fractional flow reserve. <i>JACC: Cardiovascular Imaging</i> , <b>2015</b> , 8, 1-10	8.4	183
58	Nonatherosclerotic coronary artery disease in young women. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 814-9	3.8	164
57	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 96-118	15.1	157
56	Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 635-62	3.8	135
55	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1290-1301	15.1	133
54	Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 1553-68	3.8	126
53	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 214-233	3.8	125
52	Angiographic appearance of spontaneous coronary artery dissection with intramural hematoma proven on intracoronary imaging. <i>Catheterization and Cardiovascular Interventions</i> , <b>2016</b> , 87, E54-61	2.7	114
51	Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 837-49	3.8	97
50	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 1129-1150	3.8	62
49	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1553-1563	3.8	58
48	Introducing the Placebo Effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2018</b> , 9, 1023-1033	10.3	55

47	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 1124-1135	16.2	46
46	Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology/Canadian Society of Cardiac Surgery position statement on revascularization--multivessel coronary artery disease. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 1482-91	3.8	40
45	Spontaneous Coronary Artery Dissection Misdiagnosed as Takotsubo Cardiomyopathy: A Case Series. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 1073.e5-8	3.8	38
44	Simplified Canadian Definition for Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1210-1214	3.8	36
43	Development of Cardiovascular Quality Indicators for Rheumatoid Arthritis: Results from an International Expert Panel Using a Novel Online Process. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1548-55	4.1	35
42	Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 985-95	15.1	34
41	Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 545-52	6	34
40	Statin use and risk for cataract: a nested case-control study of 2 populations in Canada and the United States. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 1613-9	3.8	33
39	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 355-362	5.5	32
38	Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery. <i>Heart</i> , <b>2016</b> , 102, 763-9	5.1	30
37	Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. <i>Cardiovascular Research</i> , <b>2018</b> , 114, 1073-1081	9.9	29
36	Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2009</b> , 2, 320-7	5.8	26
35	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , <b>2016</b> , 39, 137-44	3.3	25
34	Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2682-2693	15.1	24
33	Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 2297-2305	15.1	24
32	Changes in left ventricular function after spontaneous coronary artery dissection. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 149-154	3.3	21
31	Validation of an automated method for assessing brachial artery endothelial dysfunction. <i>Canadian Journal of Cardiology</i> , <b>2002</b> , 18, 259-62	3.8	20
30	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , <b>2016</b> , 133, 2094-8	16.7	18

29	Validation of a new ultrasound method for the measurement of carotid artery intima medial thickness and plaque dimensions. <i>Canadian Journal of Cardiology</i> , <b>2004</b> , 20, 1355-9	3.8	18
28	Angiotensin II type 1 receptor blocker inhibits pulmonary injury. <i>Clinical and Investigative Medicine</i> , <b>2005</b> , 28, 118-26	0.9	17
27	Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1004-1009	3.8	16
26	Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial). <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 1673-73	3.7	14
25	Association of skin cholesterol content, measured by a noninvasive method, with markers of inflammation and Framingham risk prediction. <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 1313-6	3	14
24	Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2049-2058	15.1	12
23	Cardiology patient page. Spontaneous coronary artery dissection (SCAD). <i>Circulation</i> , <b>2015</b> , 131, e3-5	16.7	12
22	Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2019</b> , 12, e005079	5.8	11
21	Emerging concepts: angiotensin-converting enzyme inhibition in coronary artery disease. <i>Cardiovascular Drugs and Therapy</i> , <b>1996</b> , 10 Suppl 2, 609-12	3.9	10
20	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. <i>Atherosclerosis</i> , <b>2018</b> , 277, 419-424	3.1	10
19	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 1282-92	3.8	9
18	The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia. <i>Clinical Cardiology</i> , <b>2018</b> , 41, 888-895	3.3	8
17	Comparison of cardiovascular risk assessment algorithms to determine eligibility for statin therapy: implications for practice in Canada. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 661-6	3.8	7
16	Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2197-2207	15.1	6
15	Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. <i>Canadian Journal of Cardiology</i> , <b>2002</b> , 18, 1309-16	3.8	6
14	Warfarin Monotherapy in Atrial Fibrillation Patients With Stable Coronary Disease One Year After Myocardial Infarction/Stent: Two Birds With One Stone?. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 1070-2	3.8	5
13	Are Statins out in the COLD? The STATCOPE Trial. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 970-3	3.8	4
12	Redefining the normal angiogram using population-derived ranges for coronary size and shape: validation using intravascular ultrasound and applications in diverse patient cohorts. <i>International Journal of Cardiovascular Imaging</i> , <b>2007</b> , 23, 441-53	2.5	4

11	A Plaque Disruption Index Identifies Patients with Non-STE-Type 1 Myocardial Infarction within 24 Hours of Troponin Positivity. <i>PLoS ONE</i> , <b>2016</b> , 11, e0164315	3.7	4
10	Is it Time to Update How Suspected Angina Is Evaluated prior to the Use of Specialized Tests Implications Based on a Systematic Review. <i>Cardiology</i> , <b>2016</b> , 133, 181-90	1.6	4
9	Effect of baseline exercise capacity on outcomes in patients with stable coronary heart disease (a post hoc analysis of the clinical outcomes utilizing revascularization and aggressive drug evaluation trial). <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 1509-15	3	2
8	GOAL Canada: Physician Education and Support Can Improve Patient Management. <i>CJC Open</i> , <b>2020</b> , 2, 49-54	2	2
7	Can We Eliminate Low-Density Lipoprotein Cholesterol-Related Cardiovascular Events Through More Aggressive Primary Prevention Therapy?. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 546-551	3.8	2
6	Association of "hypertriglyceridemic waist" with increased 5-year risk of subclinical atherosclerosis in a multi-ethnic population: a prospective cohort study. <i>BMC Cardiovascular Disorders</i> , <b>2021</b> , 21, 63	2.3	2
5	Evidence, Guidelines, and Gut Checks: Musings on Entering the Post-Statin Era of Lipid Management. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 271-4	3.8	1
4	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 1837-1845	3.8	1
3	Familial Hypercholesterolemia, Familial Combined Hyperlipidemia, and Elevated Lipoprotein(a) in Patients With Premature Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 1733-1742	3.8	1
2	The Two-Edged Sword of Shared Clinical Decision-Making in the Post-ISCHEMIA World of Stable Coronary Artery Disease Management: Clinical Commentary on "It Happened So Fast □ Guess, Yes, I Was Lucky". <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2020</b> , 13, e006451	5.8	0
1	Optimizing the Prevention of Cardiovascular Events. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, S13-4	3.8	